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ABSTRACT
The outcome of 55 patients who underwent matched unrelated donor (MUD) transplantation for acute
myelogenous leukemia (AML) following a conditioning regimen of cyclophosphamide and total-body irradi-
ation (TBI) with the addition of Alemtuzumab 10 mg/kg/day on days 5 to 1 is described. All patients
received graft-versus-host diesase (GVHD) prophylaxis with cyclosporine as well as 3 doses of posttransplant
methotrexate. Forty-one patients were transplanted in complete remission (CR) (20 in CR1, 20 in CR2, and 1
in CR3), and 14 were not in remission at the time of transplantation as they were refractory to chemotherapy
either at induction or at relapse. The group consisted of adult patients with a median age of 37 years.
Thirty-five patients were fully matched at HLA-A, -B, -C, and -DRB1. All patients engrafted and there were
no cases of graft rejection. Grade II-IV acute GVHD occurred in only 2 patients. Chronic GVHD developed
in 30% of patients but was extensive in only 3 cases. The predicted TRMwas 11% at day 100 and 26% at 1 year.
In multivariate analysis the receipt of an HLA mismatched transplant was associated with a higher transplant-
related mortality (TRM) (55% versus 15%). Twelve of the 14 transplant-related deaths were due to infection.
The 5-year cumulative incidence of relapse was 36% for the whole group and 28% for patients in CR at
transplantation. The 5-year cumulative survival for the whole group was 38% and was 49% for those in
remission at transplantation. Seven of the 12 patients transplanted in CR1 with adverse risk cytogenetics
remain alive and in remission, and the predicted 5-year overall survival (OS) for this group is 50%. These
results support the use of Alemtuzumab for unrelated donor hematopoietic stem cell transplant (HSCT) for
poor risk AML in CR1 and for relapsed AML in CR2. The addition of Alemtuzumab is highly effective in
preventing both rejection and severe acute and extensive chronic GVHD without an increased relapse risk.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (HSCT) remains the only potential curative ther-
py for patients with relapsed or poor risk acute leu-
emia, because both the high-dose chemo/
adiotherapy and the graft-versus-leukemia effect
GVL) contribute to disease-free survival. In the ab-
ence of a matched related donor, searches of the
ational and international registries can now identify a
24n HLA-compatible unrelated donor (UD) in up to
0% of patients [1]. However, the high rates of both
cute and chronic graft-versus-host disease (aGVHD
nd cGVHD) observed after UD transplants are re-
ponsible for increased toxicity and mortality in these
atients, resulting in inferior survival rates compared to
ransplants frommatched sibling donors. Indeed, despite
mprovements in HLA typing, the rates of grade III-IV
GVHD in fully matched non-T-depleted UD trans-
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Myeloablative MUD Transplants and Alemtuzumab for AML 725lant patients still exceed 30% in many large series
2,3]. A number of factors are known to inﬂuence
he incidence and severity of GVHD, including
atient age, degree of HLA-matching, donor sex,
ytomegalovirus (CMV) status, and stem cell dose
eceived.
T cell depletion of the graft is the most effective
trategy for the prevention of GVHD, but is associ-
ted with a higher incidence of graft failure and re-
apse after HSCT [4]. An alternative strategy is to use
retransplant serotherapy to induce in vivo T cell
epletion. The objective is to ensure engraftment of
he donor stem cells, and, because of the long half life
f the antibodies, to achieve in vivo T cell depletion of
he graft and a reduced risk of GVHD. To exploit this
ffect a number of groups have incorporated antithy-
ocyte globulin (ATG) into their preparative regi-
ens [5-9]. These studies have conﬁrmed that the
ddition of ATG pretransplant reduces the risk of
evere aGVHD, the incidence of extensive cGVHD,
nd of nonrelapse mortality (NRM) [8-10]. This has
ed to the results of UD approaching those of matched
ibling donor transplants in some series [11-13]. How-
ver, there are also disadvantages to this approach
ecause there is evidence for delayed immune recon-
titution and a higher risk of infectious complications
nd of disease relapse [14]. Campath anti-CD52 anti-
odies can also be utilized for the prevention of
VHD, because the CD52 antigen is expressed on T,
, and NK cells, but not on hemopoietic cells [15].
ampath is effective as GVHD prophylaxis when used
or ex vivo T cell depletion of the graft (“Campath in
he bag”) [16] or by using in vivo Campath pretrans-
lant [6,17].
Here, we report the use of pretransplant in vivo
ampath 1H (Alemtuzumab) in a group of 55 adult
atients undergoing myeloablative UD transplanta-
ion for acute myelogenous leukemia (AML). Our
esults conﬁrm that this regimen is highly effective at
reventing graft rejection as well as severe aGVHD
nd extensive cGVHD, whereas resulting in long-
erm survival in approximately 50% of all patients who
ere in remission at the time of transplant.
ATIENTS AND METHODS
atients
Between September 1996 and January 2006, 55 con-
ecutive patients (Table 1) with a median age of 37 years
eceived UD HSCT for AML at a single center. The
ajority of patients had been entered into the Medical
esearch Council (MRC) AML 10, 12, or 15 trials, and
ere in complete remission (CR) CR1 (n  20) or
R2 (n  20). One patient was in CR3, and 14
atients were not in remission at the time of trans-
lantation as they were refractory to chemotherapy, Tither at remission induction (n  12) or at relapse
Table 1). For patients in CR2 the median ﬁrst remis-
ion duration was 0.9 years (range 0.2-2.2). Patients
ransplanted in CR1 had either adverse risk cytoge-
etics (n  12) as deﬁned by the MRC criteria [18] or
ad intermediate risk cytogenetics and had disease
esistant to ﬁrst-line induction chemotherapy (n  6),
eﬁned by the MRC criteria [19]. In addition 1 case
as secondary to myelodysplasia and the remaining
atient had biphenotypic leukemia with bone marrow
ecrosis and no cytogenetic result could be obtained.
f the patients transplanted in CR2 the majority had
ntermediate (n 12) or good-risk (n 6) cytogenetics
ather than poor-risk cytogenetics (n 2) as it was our
olicy to transplant these cases in CR1. In 34 cases
ither the patient, the donor, or both were CMV
ositive. CMV status posttransplant was monitored by
eekly qualitative PCR and antigenemia, and patients
ho reactivated CMV were treated with ganciclovir or
oscarnet.
Thirty-four patients received bone marrow (BM)
nd 21 received granulocyte-colony stimulating factor
G-CSF) mobilized peripheral blood stem cell trans-
lantation (PBSC). Since 1999, PBSC was requested
or all patients; however, the ﬁnal choice between BM
nd PBSC was decided by the donor in conjunction
ith the UD registry policy. During this period 21 of
5 (47%) transplants were from PBSC. For patients
eceiving PBSC, a total of 4  106/kg CD34 cells
ere requested, and for patients receiving BM, a total
ononuclear cell count of 3  108/kg was re-
uested.
istocompatibility
Donors were recruited from the Anthony Nolan
able 1. Patient Characteristics
ge 36.72 (16.42-57.77)
ex: male/female 22/23
emission status of patient at transplant
● CR1 20
● CR2 20
● CR3 1
● Not in remission 14
M cytogenetics
● Favorable 6
● Intermediate 27
● Unfavorable 21
● Unknown 1
onor and recipient CMV seronegative 21
D34 cell dose  106/kg 3.57 (1.03-18.6)
egree HLA Match at HLA-A, -B, -C, and
DRB1:
● Fully matched 35
● 1 antigen mismatch 16
● 2 antigen mismatch 4
ata are median (range).
MV indicates cytomegalovirus; CR, complete remission.rust (n  39) and British Bone Marrow Registries
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E. P. Das-Gupta et al.726n  3), and where necessary, the European and Amer-
can Registries (n  13). The methods of tissue typing
ave changed over the past 10 years, and conse-
uently, the resolution obtained prior to transplanta-
ion has also changed over that time. In view of this, a
omparison of outcomes based solely on the original
issue typing data seemed inappropriate. For the ma-
ority of patients we were able, however, to obtain
etrospective high-resolution results (to 4 digits) from
he Anthony Nolan Trust for the HLA-A, -B, -C, and
DRB1 alleles, and therefore, only matching at these
oci was considered in this analysis. When the retro-
pective high-resolution data was included, 80% of
he pairs in our analysis had high-resolution typing
erformed at HLA-A, -B, -C, and -DRB1. All of the
ismatches identiﬁed at these loci were antigenic,
xcept in 1 pair with a B and C mismatch, where the
was an antigenic mismatch and the B alleleic. In the
emaining cases, the tissue typing was a mixture of
edium and low resolution. Only 2 pairs had low-
esolution typing alone, and in both cases mismatches
ere identiﬁed. In 35 cases the patient and donor were
ully matched at HLA-A, -B, -C, and -DRB1. A total
f 16 patients received a 1-locus antigen mismatched
ransplant at HLA-A (n  10), HLA-C (n  5), and
LA-DRB1 (n  1). Four patients received trans-
lants mismatched at 2 loci.
onditioning Regimen and GVHD Prophylaxis
All patients received an identical conditioning reg-
men comprising total body irridiation (TBI) 14.4 Gy
n 6 fractions over 3 days and cyclophosphamide (60
g/kg 2). In addition, all patients received pretrans-
lant immunosuppression with Alemtuzumab, 10 mg/
ay, days 5 to 1 (total dose 50 mg). For additional
VHD prophylaxis all patients received Methotrexate
10 mg/m2) on days 1, 3, and 6 and Cyclosporin
was administered from day 1 at a dose of 2.5
g/kg by mouth to maintain a blood level of 150-250
g/nL. In the absence of GVHD, cyclosporine was
apered from day 50 with the aim to discontinue ther-
py by 6 months.
efinitions
Acute GVHD was graded 0 to IV according to
tandard criteria [20]. Patients dying before day 30
osttransplant were excluded from the analysis of
GVHD. cGVHD was assessed in patients surviving
90 days from the time of transplant and was deﬁned
s limited or extensive [21]. Neutrophil engraftment
as deﬁned as the ﬁrst of 3 consecutive days with an
bsolute neutrophil count of 0.5  109/L or above.
latelet engraftment was deﬁned as the ﬁrst of 7 days
ith platelet counts of 20  109L or above without
ransfusion. otatistics
Statistical analysis was performed using SPSS
v.9.0) software (SPSS Inc., Chicago, IL) and “R”
oftware (R Development Core Team [2006], R
oundation for Statistical Computing, Vienna, Aus-
ria). The probabilities of overall survival (OS) and
vent-free survival (EFS) were calculated using the
aplan-Meier method, comparing the groups using
he log rank test. Estimation of the cumulative inci-
ence curves with subgroup analysis by the Gray
ethod was utilized to analyze transplant-related
ortality (TRM), relapse risk, and the incidence of
nd aGVHD and cGVHD [22]. Multivariate analysis
f factors affecting TRM and relapse risk was per-
ormed using Fine-Gray analysis [23]. In the univari-
te analyses for OS, TRM, and relapse the following
actors were considered using the log rank test: Stem
ell source (BM versus PBSC), patient age above or
elow the median, remission status, presence of
GVHD, presence of cGVHD, CMV status, trans-
lanted CD34 count above or below the median, cy-
ogenetic risk group, and HLA matching status. For
he univariate analyses of factors affecting the devel-
pment of aGVHD and cGVHD, donor sex, stem cell
ource, patient age, remission status, transplanted
D34 count, and HLA matching status were consid-
red. In addition, aGVHD was considered as a risk
actor for cGVHD.
ESULTS
The data were analyzed on April 5, 2006. Twenty-
our patients remained alive on this date, with a me-
ian follow-up of 4.7 years (range 0.5-9.2).
ngraftment and CMV Reactivation
Fifty-one of 52 evaluable patients achieved sus-
ained donor engraftment. The remaining patient
ailed to recover her platelet count prior to her death
rom pneumonia at 8 months posttransplant. This
atient, however, developed anti-HPA antibodies
gainst her donor’s platelets and a bone marrow ex-
mination at 2 months posttransplant demonstrated
he presence of megakaryocyte engraftment. The me-
ian time to neutrophil engraftment of 0.5  109/L
as 14 days (10-26) and for platelet engraftment of
20  109/L was 16 days (11-40). Sixteen of the 34
atients with the potential to reactivate CMV did so
osttransplant, as assessed by in-house qualitative
CR and antigenemia assays. The median number of
pisodes of CMV reactivation was 1 (0 to 4). One of
hese patients died of CMV pneumonitis despite treat-
ent with ganciclovir and foscarnet. None of the
thers went on to develop CMV disease.
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Myeloablative MUD Transplants and Alemtuzumab for AML 727GVHD and cGVHD
Nineteen of 53 evaluable patients developed
GVHD. In 17 patients this was grade I, and clinically
igniﬁcant GVHDwas seen in only 2 patients (1 grade II
nd in 1 grade IV). The 1 patient who developed grade
V aGVHD was mismatched at both HLA-A and
LA-C loci, and was in relapse at transplant. The only
actor associated with a higher incidence of aGVHDwas
he receipt of PBSC as opposed to bone marrow derived
tem cells (P  .01; Figure 1). The presence of an HLA
ismatch did not signiﬁcantly have an impact on the
evelopment of acute GVHD (P  0.47).
Fourteen of 42 evaluable patients developed
GVHD, and the cumulative incidence of cGVHD
as 30%. cGVHD was limited in 11 cases and exten-
ive in 3 cases. Six of the 14 patients were recipients of
BSC and the remaining 8 received BM. The median
ime to the onset of cGVHD was 175 days (range
05-244 days) after transplantation. Five patients were
iagnosed with GVHD after their cyclosporine was
iscontinued. Three of these had limited GVHD and
ere managed with a combination of topical steroid
nd short courses of oral steroids. The remaining 2 had
ore extensive disease requiring the reintroduction of
yclosporine with oral steroids. The only risk factor that
redicted the development of cGVHD on univariate
nalysis was the occurrence of aGVHD (P  .004).
RM
Fourteen patients died from transplant-related
auses between 2 days and 1.6 years posttransplanta-
Figure 1. The development of acute GVHD by cell source. Theion. Of these, 12 patients died from infection (respi- latory syncytial virus n  3, inﬂuenza A n  1, CMV
 1, PCP n 1, methicillin resistant staphylococcus
ureus n  1, Candida Glabrata n  1, and 4 cases of
neumonia in which no organism was identiﬁed). In
ddition, 1 patient died from aGVHD and 1 from
utoimmune hemolysis. The predicted TRM at day
00 was 11% and at 1 year was 26%. The predicted
RM of the whole group at 5 years was 27%. The
-year probability of TRM was 55% for patients with
ny degree of HLA mismatch compared to 15% for
of PBSC was associated with the development of acute GVHD.
igure 2. The effect of HLA match on TRM. Patients who were
ully matched at HLA-A, -B, -C, and -DRB1 had a signiﬁcantly
ower TRM than those with any degree of HLA mismatch.
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E. P. Das-Gupta et al.728hose transplanted from an HLA-A, -B, -C, and
DRB1 matched donor (P  .02; Figure 2). In multi-
ariate analysis, the degree of HLA match remained
he only signiﬁcant factor affecting TRM. Although
atients above the median age at transplant tended to
ave a higher TRM, this was not signiﬁcant in the
nivariate (P  .08) or multivariate (P  .06) analyses.
elapse
Eighteen patients have relapsed at a median of
igure 3. Effect of Remission Status at Transplant on Relapse (A)
igniﬁcantly more likely to relapse than those transplanted in remiss
resence of chronic GVHD protected against relapse. The Effect of
C); Cytogenetic risk group predicted for relapse in patients who w46 days (range 66-524 days). The 3- and 5-year rumulative incidence of relapse were both 36%.
he 5-year cumulative incidence of relapse for pa-
ients in remission at the time of transplantation was
8% compared to 57% for those not in remission
P  .01; Figure 3A). The 5-year probability of relapse
or patients in CR1 was 42% compared to 16% for those
atients in CR2 (P .07). The presence of aGVHD did
ot have an impact on the probability of relapse; how-
ver, the development of cGVHD protected against re-
apse (P  .012; Figure 3B). The 5-year probabilities of
ts who were not in remission at the time of transplantation were
he Effect of Chronic GVHD Post-Transplant on Relapse (B); The
netic Risk Group on Relapse for Patients in CR at Transplantation
remission at the time of transplantation.; Patien
ion. T
Cytogeelapse for patients in remission at the time of transplan-
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Myeloablative MUD Transplants and Alemtuzumab for AML 729ation with good, intermediate, and adverse risk cytoge-
etics were 0%, 21%, and 51%, respectively (P  .06;
igure 3C) In multivariate analysis, 2 factors—remission
tatus at transplant (P  .04) and cytogenetic risk group
P  .04)—affected the probability of relapse. Of the 12
atients with adverse risk cytogenetics who were trans-
igure 4. Overall survival of the whole group (A). The effect of rem
ransplanted in remission had a signiﬁcantly better OS. The Effect o
C, and -DRB1 loci had a trend toward better OS.lanted in CR1, 5 have relapsed. aurvival
The 5-year cumulative survival for the whole
roup was 38% (Figure 4A). For those in CR, it was
9% compared to 7% for those not in CR at trans-
lantation (P.0001; Figure 4B). No other factor had
status at the time of transplantation on OS (B). Patients who were
match on OS (C). Patients who were fully matched at HLA-A, -B,ission
f HLAn impact on OS. Despite the fact that HLA mismatch
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E. P. Das-Gupta et al.730as associated with a higher TRM, this did not trans-
ate to a signiﬁcant reduction in OS, although there
as a trend toward a worse outcome in the HLA
ismatched group (Figure 4C). We also analyzed fac-
ors affecting the survival of 40 patients in CR at
ransplantation. No one factor was identiﬁed on uni-
ariate analysis that signiﬁcantly had an impact on OS
n this group of patients. Of the 12 patients with
oor risk cytogenetics who were transplanted in
R1, 7 remain alive, 5 of whom are over 1 year
osttransplant including 3 patients who are over 6
ears posttransplant. The predicted 5-year OS for
hese patients is 50%.
ISCUSSION
The role of UD transplantation in AML remains
ontroversial, primarily because of the toxicity and
ortality reported from high rates of both aGVHD
nd cGVHD. Our policy has been to consider high-
isk AML patients in CR1 and patients in CR2 (ex-
luding FAB type M3) for UDHSCT. Our strategy to
revent GVHD and graft rejection has been to use
retransplant in vivo Alemtuzumab to induce T cell
epletion in the recipient. We have previously re-
orted this approach to be as effective as combined
re- and posttransplant Campath therapy [6]. Here we
resent mature outcome data relating to 55 patients
ransplanted for AML from a UD after standard cy-
lophosphamide and TBI-based conditioning with the
ddition of pretransplant Alemtuaumab.
In agreement with our previous report [6], pre-
ransplant Alemtuzumab was highly successful in pre-
enting both rejection and severe aGVHD and exten-
ive cGVHD. We observed no cases of graft rejection,
nd although aGVHD developed in 19 patients, this
igure 4. (continued)as restricted to grade I in 17 cases and grade II in mnother case. The single case of grade IV aGVHD in
his study received a transplant that was mismatched at
oth the HLA-A and -C loci. cGVHD developed in
4 cases but was only extensive in 3, and the develop-
ent of aGVHD or cGVHD did not have an impact
n OS. Although posttransplant methotrexate was
sed as additional GVHD prophylaxis in these pa-
ients it is not clear given the low rate of GVHD that
his is necessary, and our current policy is to omit this
reatment in high-risk patients. Most nonrelapse
eaths resulted from infection, suggesting that al-
hough Campath was highly effective at preventing
VHD following mismatched transplants, these pa-
ients had slow immune reconstitution leading to a
isk of posttransplant infections.
This article also highlights the importance of
igh-resolution HLA typing to avoid mismatches that
ay remain unrecognized when only medium- or
ow-resolution typing methods are used. For patients
ully matched by high-resolution typing at HLA-A,
B, -C, and -DRB1 the predicted TRM at 5 years was
nly 15% compared to 55% for patients with a mis-
atch. This was also reﬂected as a trend toward a
oorer OS, although this did not reach signiﬁcance.
ther recent studies have shown the importance of
llele level typing to identify “hidden mismatches”
o improve the outcome of UD transplantation
2,3,24,25]. These studies all suggest (whether T cell
epleted or T cell replete) that mismatched pairs have
higher incidence of transplant complications. Even
ith a 10/10 matched donor the incidence of GVHD
n T cell-replete transplants exceeds that of T cell-
eplete transplants. One difference appears to be that
ingle mismatches may be tolerated with regard to OS
n T cell-depleted transplants (where this is not re-
orted to be the case with T cell-replete transplants).
owever, as can be seen in this study, there is evi-
ence that even in T cell-depleted transplants the
RM is higher in mismatched pairs.
The use of T cell depletion might be expected to
ave a negative impact on disease relapse [4]; however,
or patients in CR at transplant the relapse risk was
8% and the risk of relapse was related to the cyto-
enetic risk group and remission status at transplan-
ation. Despite this, for the 12 patients with poor-risk
ytogenetics who were transplanted in CR1, the pre-
icted 5-year OS is 50%. Although not signiﬁcant, the
robability of relapse for patients transplanted in CR2
as lower than for those transplanted in CR1. This
as a surprising ﬁnding, as the reverse situation might
ave been expected based on other reported series
26,27]. The ﬁnding probably reﬂects the cytogenetic
pread of patients between the 2 groups. Patients
ransplanted in CR1 included 7 intermediate- and 12
oor-risk patients with no good-risk patients. Those
ransplanted in CR2 included 6 good-risk, 12 inter-
ediate-risk, and only 2 poor-risk patients. The re-
l
(
[
s
p
O
o
i
v
T
b
t
c
b
h
b
r
c
d
p
3
I
d
r
i
t
A
d
w
p
a
i
o
2
v
o
a
c
n
t
p
t
l
e
m
f
t
c
A
c
t
c
t
n
g
c
r
t
b
t
u
r
T
w
m
o
t
a
c
5
s
g
8
p
A
e
f
e
d
c
t
a
t
y
t
t
5
r
w
d
f
o
a
p
w
-
O
a
t
e
R
Myeloablative MUD Transplants and Alemtuzumab for AML 731apse risk for patients not in CR at transplant was high
80%) in keeping with previous observations
26,28].
It is difﬁcult to compare our results with other
eries of UD HSCT for AML, as almost half the
atients in our group were over the age of 40 years.
ther published series have reported median ages
f at least 10 years lower [17,29,30]. Increasing age
s a risk factor for TRM in patients receiving con-
entional allografts as treatment for AML [31,32].
he fact that this was not reﬂected in this series may
e related to the higher age of the group as a whole.
An alternative method of transplanting these pa-
ients would have been to use a reduced intensity
onditioning (RIC) regimen, an approach that has
een used by a number of groups. Wong et al. [33]
ave reported the use of ﬂudarabine- and melphalan-
ased regimens that included ATG in the preparative
egimen. They undertook 29 MUD transplants in-
luding 16 for patients with AML or high-risk myelo-
ysplastic syndromes (MDS). Their estimated OS and
rogression-free survival (PFS) rates at 1 year were
8% and 34%, respectively. Their rate of grade II to
V aGVHD was 41%. Eight of 16 evaluable patients
eveloped extensive cGVHD. Martino et al. [34] have
eported the use of a ﬂudarabine and busulfan regimen
n the context of HLA-identical sibling transplanta-
ion for 37 patients with AML or high-risk MDS.
lthough they had a short median follow-up of 297
ays, their 1-year incidence of TRM was only 5%,
ith a 1-year PFS of 66%. In a larger study of 76
atients with high-risk AML or MDS who received an
llograft using a ﬂudarabine/melphalan RIC regimen
ncorporating Alemtuzumab, the day 100 TRM was
nly 9%, and no patient developed greater than grade
GVHD [35]. The 3-year OS and disease-free sur-
ival (DFS) for patients with AML in CR at the time
f transplantation were 48% and 42%, respectively,
nd the risk of disease relapse at 40% was the most
ommon cause of treatment failure. Taken together,
one of the OS ﬁgures in these reports are superior to
hose reported here. In a direct comparison of trans-
lant outcome in 150 patients with MDS or AML
ransformed from MDS receiving either matched re-
ated donor (MRD) or MUD transplants using my-
loablative or nonmyeloablative conditioning regi-
ens, Scott et al. [36] have shown similar OS and PFS
or the 2 types of conditioning. In a larger study from
he European Blood and Marrow Transplant, the out-
omes of 722 patients over the age of 50 years with
ML who received either an RIC or a myeloablative
onditioning regimen in an HLA identical sibling set-
ing were compared [37]. A signiﬁcant reduction in
GVHD and NRM was noted in the RIC group, but
he relapse rate was signiﬁcantly higher and there was
o difference in the 2-year RFS/OS between the 2
roups. The long-term beneﬁts of RIC regimens inomparison to conventional myeloablative regimens
emain to be clariﬁed, and no disease-speciﬁc prospec-
ive trials comparing the results of RIC with myeloa-
lative HSCT have been published. The use of pre-
ransplant Alemtuzumab in our regimen has enabled
s to undertake myeloablative transplantation with a
educed incidence of GVHD and day 100 and 1-year
RM of 11% and 26%, respectively, and in patients
ith a matched donor our results support the use of
yeloablative conditioning regimens as the treatment
f choice.
The alternative treatments to UD HSCT for
hese patients include chemotherapy alone or an
utograft. For poor-risk patients in CR treated with
hemotherapy alone in the MRC AML10 trial, the
-year OS and relapse rate was 17% and 75%, re-
pectively [19]. Similarly, the EORTC-GIMEMA
roup reported an EFS of 12% and relapse risk of
7% [38]. We only had 12 patients in this series with
oor risk cytogenetics who were transplanted in CR1.
ccepting the selection bias in our group who were ﬁt
nough for a UD HSCT, we feel that the 50% OS
ollowing this Alemtuzumab-containing regimen is
ncouraging. For patients in CR2 without a sibling
onor the other options available are an autograft or
hemotherapy. A study from the MRC AML10 and 12
rials has shown that MUD transplant and autograft
re signiﬁcantly superior to chemotherapy in this pa-
ient group, with an OS of 40%, 33%, and 22% at 5
ears and a relapse risk of 38%, 59%, and 71% for UD
ransplants, autografts, and chemotherapy, respec-
ively [39]. Our study demonstrated a 5-year OS of
1%, with a 20% risk of relapse for patients in CR2;
esults are comparable to those that can be achieved
ith sibling transplantation. We propose that these
ata support the use of UD HSCT in AML in CR2
or those patients lacking a sibling donor.
In summary, our results demonstrate the efﬁcacy
f pretransplant Alemtuzumab in reducing GVHD
nd rejection in patients undergoing UD HSCT for
oor risk AML in CR1 and for relapsed AML in CR2
ho have a donor matched at HLA-A, -B, -C, and
DRB1. Furthermore, as patient age had no effect on
S, older patients up to 50 years are suitable for this
pproach. For patients not in remission at the time of
ransplantation the results were poor, and other strat-
gies not involving in vivo T cell depletion are needed.
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